Cargando…
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Rasagiline is a monoamine oxidase B inhibitor with demonstrated efficacy and safety in patients with Parkinson’s disease (PD). We recently conducted the first randomized, double-blind, placebo-controlled trial of rasagiline in Japanese patients with early PD and now report the results of its open-la...
Autores principales: | Hattori, Nobutaka, Takeda, Atsushi, Takeda, Shinichi, Nishimura, Akira, Kitagawa, Tadayuki, Mochizuki, Hideki, Nagai, Masahiro, Takahashi, Ryosuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449288/ https://www.ncbi.nlm.nih.gov/pubmed/30689042 http://dx.doi.org/10.1007/s00702-018-1964-3 |
Ejemplares similares
-
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019) -
Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021) -
Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
por: Hattori, Nobutaka, et al.
Publicado: (2022) -
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022) -
The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study
por: Hattori, Nobutaka, et al.
Publicado: (2022)